Merck Raises EPS Outlook After Q2 Earnings

Health and Healthcare

Published: July 29, 2016 8:20 am

Last Updated: January 13, 2020 5:08 am

Drug giant Merck & Co. Inc. (NYSE: MRK) reported second-quarter 2016 results before markets opened Friday. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.93 and revenues of $9.84 billion. In the same period a year ago, Merck reported EPS of $0.86 on revenues of $9.79 billion. Second-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.91 and $9.78 billion in revenues.

Pharmaceutical sales rose 2% year over year, irrespective of currency exchange effects. Net income on a GAAP basis totaled $1.21 billion, while non-GAAP net income totaled $687 million. Non-GAAP net income excludes the impacts of $1.12 billion in expenses related to acquisitions and divestitures, $18 million in marketing and administrative expenses, and $207 million in R&D costs.

In its financial outlook statement, Merck raised the lower end of its full-year adjusted EPS estimate from $3.60 to $3.67. The top end of the range rose from $3.75 to $3.77. Revenue guidance remained at $39.1 billion to $40.1 billion.

Consensus estimates for the third quarter call for EPS of $0.98 and revenues of $10.07 billion. For the full year, analysts are looking for EPS of $3.72 and revenues of $39.49 billion.

Chairman and CEO Kenneth C. Frazier said:

Our results this quarter reflect our strategic focus on key launches, including KEYTRUDA and ZEPATIER, as well as our priority inline programs. We remain committed to advancing our pipeline, delivering a balanced and differentiated portfolio, and achieving long-term, sustainable growth.

Since the beginning of the year, Merck stock trades up about 10.6%, well above the Dow Jones Industrial Average gain of 5.9%. Over the past 12 months, however, Merck stock trades down about 0.2%, compared with a Dow gain of 4%.

Shares of Merck’s stock traded up nearly 1.5% in Friday’s premarket, at $59.30 in a 52-week range of $45.69 to $60.07. Thomson Reuters had a 12-month price target of $61.90 before the report.

Get Ready To Retire ^(Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future